Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074394 | 1.00 | MEN1 (0.48) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL15573155 | 1.00 | MEN1 (0.48) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1469903 | 1.00 | MEN1 (0.48) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905004 | 0.84 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905152 | 0.84 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905280 | 0.84 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL24477696 | 0.81 | CYP2C19 (0.41) | MEN1KMT2AL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL21424377 | 0.81 | CYP2C19 (0.41) | MEN1KMT2AL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL21942173 | 0.81 | CYP2C19 (0.41) | MEN1KMT2AL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL13344775 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2019-11-19 | — | — | US | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017146186-A1 | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | 塩野義製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-8629133-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629133-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | MEN1 2066/4885KMT2A 1997/4885L3MBTL1 398/4885 |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | MEN1 3507/4885KMT2A 4571/4885L3MBTL1 2247/4885 |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | MEN1 2066/4885KMT2A 1997/4885L3MBTL1 398/4885 |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | MEN1 2066/4885KMT2A 1997/4885L3MBTL1 398/4885 |
| US-10478425-B2 | 5-phenylazaindole derivative having AMPK-activating activity | PRKAG2, PRKAG1, PRKAB2 | MEN1 3965/4885KMT2A 666/4885L3MBTL1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.